维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="RUTER B"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Continued low-dose decitabine(DAC) is an active first-line treatment of older AML patients:first results of a multieenter phase Ⅱ study 显示文摘	Lubbert M Ruter B Schmid M	2005	Blood2005，106，4：	1
2	DNA hypermethylation of myeloid cells,a novel therapeutic target in MDS and AML显示文摘	Muller CI Ruter B Koeffler HP	2006	Curr Pharm Biotechnol2006，7，5：	1
3	Altering regulatory T cell function in cancer immunotherapy:a novel means to boost the effi-cacy of cancer vaccines显示文摘	Ruter J Barnett B G Kryczek I	2009	Front Biosci2009，14，：	1
4	Efficacy of decit abine in the treatment of patients with chronic myelomonoeytic leukemia (CMML) 显示文摘	Wijermans P W Ruter B Baer M R	2008	Leuk Res2008，32，4：	1
5	Preferential cytogenetic re- sponse to continuous intravenous low-dose deeitabine (DAC) ad- ministration in myelodysplastic syndrome with monosomy 7 显示文摘	Ruter B Wijermans P Claus R	2007	Blood2007，110，3：	1
6	Ef-ficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia显示文摘	WIJERMANS P W RUTER B BAER M R	2008	Leuk Res2008，32，：	1
7	Non- intensive treatment with low-dose 5-aza-20- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients显示文摘	LUBBERT M BERTZ H RUTER B	2009	Bone Marrow Transplant2009，44，9：	1
8	Efficacy of decitabine in the treatment of patients with chronic my- elomonocytic leukemia (CMML) 显示文摘	WIJERMANS P W RUTER B BAER M R	2008	Leuk Res2008，32，：	1
9	Regulatory T cells: a new frontier in cancer immunotherapy 显示文摘	Barnett B G Ruter J Kryczek I	2008	Adv Exp Med Biol2008，622，：	1
10	Nonintensive treatment with low- dose 5- aza- 20- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients 显示文摘	Lubbert M Bertz H Ruter B	2009	Bone Marrow Transplant2009，44，9：	1
11	Continued low-dose deci- tabine (DAC) is an active first-line treatment of older AML patients :first results of a multicenter phase 1/ study显示文摘	Lubbert M Ruter B Schmid M	2005	Blood2005，106，：	1
12	Non-intensive treatment with low-dose 5-aza-2' deoxyeytidine(DAC) prior to allogeneie blood SCT of older MDS/AML patients显示文摘	Lubbert M Bertz H Ruter B	2009	Bone Marrow Transplant2009，44，：	1
13	First resuits with the trochanteric fixation nail(TFN) :a report on 120 cases显示文摘	Lenich A Mayr E Ruter A Mockl C Fuchtmeier B	2006	Arch Orthop Trauma Surg2006，126，：	1
14	The cont ro 1 ofpostharvestdecay of table grapes显示文摘	Combrink J C T ruter A B		0，，08：	1
15	Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'- deoxyeytidine retreatment in high-risk myelodysplasia patients 显示文摘	RUTER B WIJERMANS P W LUBBERT M	2006	Cancer2006，106，8：	1
16	Contin-ued low-dose decitabine (DAC) is an active first-Linetreatement of older AML patients : first results of amulticenter phase-study 显示文摘	LUBBERT M RUTER B SCHMID M	2005	Blood2005，106，：	1
17	NOx reduction from a large bore natural gas engine via reformed natural gas prechamber fueling optimization 显示文摘	RUTER M D OLSEN D B SCOTrO M V	2012	Fuel2012，91，1：	1
18	A mul- ticenter phase II trial of decitabine as first-line treat- ment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy显示文摘	LOBBERT M RUTER B H CLAUS R	2012	Haema- tologica2012，97，：	1
19	Results of 5-aza-2'- deoxycytidine retreatment in high-risk myelodysplasia patients 显示文摘	RUTER B WIJERMANS PW LUBBERT M	2006	Cancer2006，106，8：	1
20	Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7显示文摘	Ruter B Wijermans P Claus R	2007	Blood2007，110，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示